MedTrace Logo

A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes

NCT07658560 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-06-22

No results posted yet for this study

Summary

To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.

Conditions

  • Overweight or Obese Participants Without Diabetes

Interventions

DRUG

BGM0504 tablets

Administered p.o once daily

DRUG

BGM0504 tablets

Administered p.o once daily

DRUG

BGM0504 tablets

Administered p.o once daily

DRUG

BGM0504 tablets

Administered p.o once daily

DRUG

BGM0504 placebo

Administered p.o once daily

Sponsors & Collaborators

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-02-28
Completion
2027-02-28
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07658560 on ClinicalTrials.gov